Coming Up on This Page: Exclusive, On-site ASCO Coverage
Expert Perspectives: Key opinion leaders in gastrointestinal cancers, renal cell carcinoma and hematological malignancies cover the best sessions and abstracts of this year’s ASCO meeting…podcasts, interviews, on-site coverage.
Expert Perspectives: Key opinion leaders in gastrointestinal cancers, renal cell carcinoma and hematological malignancies cover the best sessions and abstracts of this year’s ASCO meeting…podcasts, interviews, on-site coverage.
Look for nationally regarded colorectal cancer (CRC) specialist and researcher, Dr. Richard Goldberg’s online analysis of the highlights in CRC coverage at this year’s ASCO meeting.
In his ASCO podcast, Dr. Goldberg, Distinguished Professor, Hematology/Oncology, at the University of North Carolina Lineberger Comprehensive Cancer Center and the Physician-in-Chief of the North Carolina Cancer Hospital, spoke about the new developments in advanced colorectal cancer since ASCO 2003 when he presented groundbreaking trial data demonstrating that the combination regimen FOLFOX (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin [Eloxatin]) should be considered standard of care in advanced CRC. Looking forward from ASCO 2003, to the development of new targeted biologics, Dr. Goldberg said, “The lay of the land has been profoundly changed in a beneficial way due to the development of these new drugs.”
Dr. Goldberg also discussed the clinical trial work that has put him at the forefront of the emerging field of pharmacogenetics, shedding light on what we have learned so far in this exciting new discipline that will help guide the use of multidrug combos in the difficult clinical setting of advanced disease. Dr. Goldberg pointed out that pharmacogenetics is emerging as an important component both in facilitating new drug development and in improving the utility of existing chemotherapeutic agents.
Stay tuned for more pre-ASCO podcasts and expert review papers by fellow guest editors, noted GI cancer expert Dr. Peter Enzinger, Assistant Professor of Medicine, Dana-Farber Cancer Institute and leading renal cell carcinoma experts, Peter Enzinger, Assistant Professor of Medicine, Dana-Farber Cancer Institute, and internationally regarded oncologist and clinical investigator, Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, New York City.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
